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Vascular smooth muscleThe rising epidemic of diabetes worldwide is of signiﬁcant concern. Although the ultimate objective is to prevent
the development and ﬁnd a cure for the disease, prevention and treatment of diabetic complications is very im-
portant. Vascular complications in diabetes, or diabetic vasculopathy, includemacro- andmicrovascular dysfunc-
tion and represent the principal cause of morbidity and mortality in diabetic patients. Endothelial dysfunction
plays a pivotal role in the development and progression of diabetic vasculopathy. Endothelin-1 (ET-1), an endo-
thelial cell-derived peptide, is a potent vasoconstrictor with mitogenic, pro-oxidative and pro-inﬂammatory
properties that are particularly relevant to the pathophysiology of diabetic vasculopathy. Overproduction of
ET-1 is reported in patients and animal models of diabetes and the functional effects of ET-1 and its receptors
are also greatly altered in diabetic conditions. The current therapeutic approaches in diabetes include glucose
lowering, sensitization to insulin, reduction of fatty acids and vasculoprotective therapies. However,
whether and how these therapeutic approaches affect the ET-1 system remain poorly understood. Accord-
ingly, in the present review, we will focus on experimental and clinical evidence that indicates a role for
ET-1 in diabetic vasculopathy and on the effects of current therapeutic approaches in diabetes on the vas-
cular ET-1 system.
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Diabetic vasculopathy, including macro- and micro-vascular disor-
ders, is the leading cause of morbidity and mortality in patients with
diabetesmellitus (DM) [type 1 (T1DM) and type 2 (T2DM)]. Endothelial
dysfunction, characterized by an imbalance between endothelium-. This is an open access article underderived relaxing factors (EDRFs) and contracting factors (EDCFs),
plays an important role on the development and progression of diabetic
vasculopathy (Forbes and Cooper, 2013; Mather, 2013; Muniyappa and
Sowers, 2013; Sowers, 2013).
Endothelin-1 (ET-1), an endothelial cell (EC)-derived peptide, is a po-
tent vasoconstrictorwithmitogenic, pro-oxidative andpro-inﬂammatory
properties that are particularly relevant to the pathophysiology of diabet-
ic vasculopathy (Callera et al., 2006; Tostes and Muscara, 2005; Kohan
et al., 2011b). Not only the expression and functional effects of ET-1
and its receptors are greatly altered in diabetic conditions, but alsothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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related vasculopathy. For instance, circulating and local levels of ET-1 are
increased in diabetic animal models and diabetic patients (Kanie et al.,
2003; Matsumoto et al., 2007, 2009; Ergul, 2011; Pernow et al., 2012).
Both ET-converting enzyme/ET-1 expression and activation of ET-1-
selective mitogen-activated protein kinases (MAPK) are increased in
the Otsuka Long-Evans Tokushima fatty (OLETF) rat, a model of T2DM
(Jesmin et al., 2006). ET-1-mediated responses are due to the activation
of two distinct G protein-coupled receptors, the ETA and ETB receptors.
ETA receptors, mainly localized in vascular smooth muscle cells
(VSMCs), contribute to the vasoconstrictor and proliferative responses
to ET-1. Activation of ETB receptors, located in VSMCs of certain vascular
beds, also induces vasoconstriction (Ergul, 2011; Pernow et al., 2012). On
the other hand, ETB receptors located in ECs lead to vascular relaxation via
the release of EDRFs such as nitric oxide (NO) and prostacyclin (PGI2).
Abnormal expression of ET-1 receptors (ETA and ETB) is detected in the
vasculature of diabetic subjects (Kobayashi et al., 2008; Matsumoto
et al., 2009; Nemoto et al., 2012a, 2012b). Thus, the comprehension of
signaling mechanisms activated by these receptors in both ECs and
VSMCs is important in diabetic vasculopathy. There are seminal recent
reviews focusing on ET-1-induced responses, the relative roles of ETA
and ETB receptors inmediating ET-1 actions, and ET-1-activated signaling
pathways in diabetic patients and animal models of diabetes (Kalani,
2008; Ergul, 2011; Pollock and Pollock, 2011; Pernow et al., 2012). There-
fore, in this reviewwewill particularly focus on the effects of therapeutic
approaches in diabetes on the vascular ET-1 system (Fig. 1).
In the face of the global epidemic of diabetes, it is critical that we
update our understanding of the pathogenesis of diabetes and related
vascular complications. This may ultimately lead to novel treatment op-
tions for prevention and/or delaying the progression of diabetic compli-
cations (Forbes and Cooper, 2013). Themechanisms regulating ECs and
VSMC function are important therapeutic targets in diabetic vascular
complications (Forbes and Cooper, 2013; Porter and Riches, 2013).
Accordingly, the regulation of the vasoconstrictor, mitogenic, pro-
oxidative and pro-inﬂammatory properties of ET-1 is undoubtedly im-
portant in diabetic complications. Although there are various therapeu-
tic approaches for the treatment of diabetes, including normalization ofFig. 1.Mechanisms by which current therapeutic interventions in diabetes modulate the vascul
effects of ETB activation may be impaired in endothelial cells. ETA (and sometimes ETB) receptor a
tone;major players in diabetic complications. ACE: angiotensin converting enzyme; AT1: angioten
receptor; ETB: ETB receptor; JNK: c-Jun N-terminal kinase; MAPK: mitogen-activated protein kina
species.glucose and fatmetabolism, few reviews have focused on how the ther-
apeutic approaches in diabetes impact the ET-1 system. In this review,
we summarize some of the experimental and clinical evidence indicat-
ing that the beneﬁcial effects of current therapeutic approaches in dia-
betes include normalization of the ET-1 system. In addition, we brieﬂy
discuss the beneﬁcial effects produced by the inhibition of the vascular
ET-1 system in diabetic vasculopathy.
ET-1 and therapeutic interventions for diabetes
Anti-diabetic drugs
Metformin is one of the most prescribed therapeutic drugs for pre-
diabetic subjects and patients diagnosed with T2DM. Metformin, a
biguanide derivate (1,1-dimethylbiguanide), acutely decreases hepat-
ic glucose production, mostly through a transient inhibition of the mi-
tochondrial respiratory chain complex I and activation of AMPK (AMP-
activated protein kinase), a cellular metabolic sensor (Viollet et al.,
2012). Sachidanandam et al. (2009) reported that glycemic control
withmetformin in Goto-Kakizaki (GK) rats, a T2DMmodel, attenuates
increased vascular media-to-lumen ratio, myogenic tone and collagen
synthesis. Metformin also normalizes plasma ET-1 levels and mesen-
teric artery ETA receptor expression in these animals, indicating that
glycemic control not only inhibits vascular remodeling and activation
of the ET-1 system, but also has preventive effects on T2DM-associated
vasculopathy. Women with polycystic ovary syndrome, who present
with hyperinsulinemia, insulin resistance, and hyperandrogenemia,
appear to be at higher risk for T2DM and exhibit elevated ET-1 levels
(Diamanti-Kandarakis and Dunaif, 2012; Imbar et al., 2012). Treat-
ment with metformin lowers ET-1 in this syndrome (Diamanti-
Kandarakis et al., 2001; Orio et al., 2005).
The thiazolidinediones, also knownas glitazones, such as rosiglitazone
and pioglitazone, are also used in the treatment of T2DM (Ahmadian
et al., 2013). Thiazolidinediones activate nuclear factor peroxisome
proliferator-activated receptorγ (PPARγ) and affect various physiological
responses, including vascular function (Iglarz et al., 2003). In VSMCs, the
PPARγ activator rosiglitazone prevents ET-1-stimulated vascular pro-ar ET-1 system and decrease diabetic vasculopathy. In diabetic states, the vasculoprotective
ctivation induces oxidative stress, inﬂammation, growth/remodeling, and abnormal vascular
sin II type 1 receptor; ERK: extracellular signal-regulated kinase; ET-1: endothelin-1; ETA: ETA
se; NF-κB: nuclear factor-kappa B; NO: nitric oxide; PGI2: prostacyclin; ROS: reactive oxygen
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cular cell adhesionmolecule 1 (VCAM-1), intercellular adhesionmolecule
(ICAM), and cyclooxygenase (COX)-2 expression (Montezano et al.,
2007). In ECs, rosiglitazone inhibits oxidized low-density lipoprotein-
induced ET-1 secretion (Martin-Nizard et al., 2002). We showed that
treatment with pioglitazone improves endothelial function by suppress-
ing oxidative stress via increased superoxide dismutase activity and
decreased NAD(P)H oxidase activity and that pioglitazone also decreases
ET-1 levels, whichmight be attributable to the inhibition of the transcrip-
tion factor activator protein-1 (AP-1) signaling (Matsumoto et al., 2007).
In T2DM patients, treatment with pioglitazone reduces urinary albumin
excretion and urinary ET-1 levels (Nakamura et al., 2000). Potenza et al.
(2006) found that treatment of spontaneously hypertensive rats (SHR),
which exhibit endothelial dysfunction and insulin resistance, with
rosiglitazone reduces blood pressure, insulin resistance, circulating ET-1
and insulin levels and increases adiponectin levels. Considering that the
beneﬁcial effects of thiazolidinediones are shadowedby some side effects,
such as the risk for ﬂuid retention, bone loss, weight gain, and congestive
heart failure (Ahmadian et al., 2013), the development of newer classes of
molecules with reduced or no adverse side effects is warranted.
The incretin glucagon like peptide-1 (GLP-1) has a well recognized
role on glucose-stimulated insulin release and the regulation of plasma
glucose homeostasis (Kim and Egan, 2008). GLP-1 receptor agonists and
inhibitors of the dipeptidyl peptidase-4 (DPP-4) enzyme,which activate
the GLP-1 system, are used in the treatment of T2DM (Russell, 2013).
Dai et al. (2013) recently found that liraglutide, a GLP-1 agonist,
decreases ET-1 expression by inhibiting the phosphorylation of NF-κB
in human umbilical vein endothelial cells (HUVECs). The incretin-
based therapy may have direct effects on endothelial integrity.
The chemical reactionwhereby proteins are glycosylated is spontane-
ous, proportional, and indiscriminate to glucose concentrations. The
in vivo relevance of the Maillard reaction, which results from a chemical
reaction between an amino acid and a reducing sugar and the subsequent
production and accumulation of advanced glycation end-products
(AGEs), was ﬁrst emphasized in studies with the inhibitor of advanced
glycation, aminoguanidine (Brownlee et al., 1986). The breakdown of
AGEs has been shown to improve endothelial function (Gao et al., 2008;
Farmer and Kennedy, 2009; Win et al., 2012). We recently reported
that treatment of T2DM rats with aminoguanidine normalizes ET-1-
induced aortic contraction by suppressing ETA receptor/extracellular
signal-regulated kinase (ERK) activities and/or by normalizing the imbal-
ance between c-Jun activation domain-binding protein-1 (Jab1) and
glycosylation with O-linked N-acetylglucosamine (O-GlcNAc) (Nemoto
et al., 2012a). Since transcription of ET-1 is regulated by NF-κB in AGE-
stimulated ECs (Quehenberger et al., 2000) and positive association of
ET-1 with AGEs is seen in polycystic ovary syndrome (Christakou et al.,
2011), the breakdown of AGE may produce beneﬁcial effects by
suppressing ET-1 expression/activity.
Blockade of the renin–angiotensin–aldosterone system
The renin–angiotensin–aldosterone system (RAAS) plays a key role
on blood pressure control via the actions of angiotensin II (Ang II) and
increased RAAS activity leads to hypertension and associated target-
organ damage Paul et al., 2006; Ruster and Wolf, 2006. Ang II type 1
receptor (AT1) antagonists have become an important drug class
in the treatment of DMdue to its protective effects on diabetic nephrop-
athy (Michel et al., 2013). A crosstalk between Ang II and ET-1 is
well established. For example, Ang II increases expression of
preproendothelin mRNA and ET-1 in ECs (Emori et al., 1991), VSMCs
(Hong et al., 2004), and vascular adventitial ﬁbroblasts (An et al.,
2007). Ang II infusion into rats increases the aortic ET-1 content, and
this is blocked by the AT1-receptor antagonist losartan (d'Uscio et al.,
1998). In contrast, ET-1 stimulates the conversion of Ang I to Ang II in
pulmonary ECs (Kawaguchi et al., 1990) and ETA receptor antagonism
reduces the vasoconstrictor responses to Ang II (Wenzel et al., 2001).Therefore, it is possible that blockade of the RAAS confers renal protec-
tion in diabetic conditions by normalizing ET-1 signaling. Indeed, we
found that treatment of T2DM GK rats with losartan normalizes ET-1-
induced mesenteric artery contraction by suppressing ERK activity
and/or normalizing endothelial function (Matsumoto et al., 2010). Sim-
ilar effects of losartanwere found in the aorta fromhyperinsulinemic di-
abetic rats (Kobayashi et al., 2008). Of importance, treatment of diabetic
patients with angiotensin converting enzyme (ACE) inhibitors lowers
plasma ET-1 levels (Iwase et al., 2000; Schneider et al., 2002).
It has been suggested that concomitant blockade of both ET-1 and
Ang II endocrine/paracrine pathways may lead to additional end-organ
protection in diabetes. Accordingly, combination of a selective ETA
receptor antagonist and an ACE inhibitor produces impressive beneﬁts,
including regression of lesions in diabetic nephropathy (Gagliardini
et al., 2009). Mohanan et al. (2011) found that TRC120038, a dual AT1/
ETA receptor antagonist, reduces hypertension and diabetic end-organ
damage in obese Zucker spontaneously hypertensive fatty rats, an
animal model of moderate hypertension, diabetes with progressive
renal and cardiac dysfunction. The effects of TRC120038 were similar,
or even better, than those produced by candesartan (Mohanan et al.,
2011). Although this compound is theoretically effective for diabetic
complications, further detailed studies on its safety and toxicity are
required to shape its use in humans. Goddard et al. (2004) found a
synergy, affecting both systemic and renal hemodynamics as well
as renal tubular function, between the effects of ETA receptor antag-
onism and ACE inhibition in humans. They suggested that these
synergic effects are due to ETB-receptor-mediated NO-dependent
mechanisms (Goddard et al., 2004). These ﬁndings show that further
investigation on selective ETA receptor blockade, over combined
ETA/ETB receptor blockade, as a useful adjunct to ACE inhibition in
the management of the systemic and renal hemodynamics is needed
(Goddard et al., 2004).
Aldosterone exerts important vascular effects by acting in the endo-
thelium, VSMCs, adventitial layer, and also in the perivascular adipose
tissue. Aldosterone inﬂuences vascular contraction, sensitizes the vas-
culature to effects of vasoconstrictors, induces growth and remodeling,
and has pro-inﬂammatory and oxidative properties (Struthers, 2004;
Schiffrin, 2006). Of importance, aldosterone levels are increased in
T1DM (Hollenberg et al., 2004) as well as in T2DM (Fredersdorf et al.,
2009). Basic and clinical studies have demonstrated that increased plas-
ma aldosterone levels predict the development of insulin resistance and
that aldosterone directly interferes with insulin signaling in the vascular
tissue (Bender et al., 2013). In addition, a crosstalk between aldosterone
and ET-1 has been documented (Rossi et al., 2001; Briet and Schiffrin,
2013). For instance, in Sprague Dawley (SD) rats, aldosterone increases
plasma ET-1 levels and induces vascular remodeling, which is prevented
by ETA receptor blockade (Pu et al., 2003). Maron et al. (2012) observed
that the elevated vascular levels of ET-1 in pulmonary hypertension are
associated with increased circulating and lung tissue levels of aldoste-
rone. In addition, the antagonism of ETA receptor attenuates blood pres-
sure elevation and prevents vascular remodeling/hypertrophy of aorta
and mesenteric resistance arteries in aldosterone-infused rats (Park
and Schiffrin, 2001). Treatment with spironolactone in streptozotocin
(STZ)-induced diabetic rats decreases renal collagen deposition and
early renal injury (Fujisawa et al., 2004).Whereas increased aldosterone
and ET-1 levels in STZ-induced diabetic rats are associated with
decreased renal expression of Dot1a, which is a splice variant of Dot1
(disruptor of telomeric silencing) and chromosome 9 (Af9) — negative
regulators of ET-1 transcription, spironolactone decreases ET-1 expres-
sion and increases Dot1a and Af9 expression in a renal proximal tubular
cell line (Zhou et al., 2012). These data reinforce the suggestion that al-
dosterone receptor antagonism is an effective intervention for diabetic
complications such as diabetic nephropathy (Heerspink and de Zeeuw,
2011). Since mineralocorticoid receptor antagonists exhibit side effects
related to blockade of androgen receptors, e.g. sexual dysfunction, gy-
necomastia and feminization (Abuannadi and O'Keefe, 2010; Funder,
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no side effects is warranted.
Other drugs
Regulation of PPARs plays an important role as therapeutic targets
against cardiovascular and metabolic diseases (Matsumoto et al.,
2008; Millar, 2013; Ferroni et al., 2013; Cheang et al., 2013). Three
isotypes of PPARs such as PPARα, PPARβ/δ (PPARβ) and PPARγ are rec-
ognized and their role on glucose and lipid metabolism is well known.
Asmentioned above, there is a crosstalk between PPARγ and ET-1 in di-
abetes, which also seems the case for PPARα or PPARβ and ET-1 signal-
ing. Fenoﬁbrate, an agonist of PPARα, not only inhibits ET-1 expression
in human ECs (Glineur et al., 2013), but also decreases ET-1-induced
p38MAPK activation in cardiomyocytes (Irukayama-Tomobe et al.,
2004a), and decreases ET-1-induced cardiac hypertrophy through
negative regulation of AP-1 binding activity and inhibition of the c-Jun
N-terminal kinase (JNK) pathway (Irukayama-Tomobe et al., 2004b).
We showed in a previous study that treatment of STZ-induced diabetic
rats with bezaﬁbrate improves endothelial function and this is associat-
ed with decreased ET-1 production (Kanie et al., 2003). Zarzuelo et al.
(2013) found that the activation of PPARβ with GW0742 (a PPARδ/
β agonist) in deoxycorticosterone acetate (DOCA)–salt hypertensive
rats normalizes endothelial function partly by reducing ET-1-induced
superoxide generation. Moreover, Quintela et al. (2012) demonstrated
that treatment of rats with T1DM (STZ-induced diabetes) and with
GW0742 restores endothelial function via an increase in NO bioavail-
ability as a result of down-regulation of prepro-ET-1 and reduced
NAD(P)H oxidase-derived superoxide generation.
The 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhib-
itors (statins) are used to lower low-density lipoprotein levels. Statins
are recognized to have pleiotropic effects (other than reducing dyslipid-
emia), including increasingNO bioavailability aswell as reducing oxida-
tive stress and inﬂammation (Lefer et al., 2001; Abdul Rahman and
Chetter, 2010; Chen et al., 2011). Moreover, statins lower ET-1 produc-
tion and prepro-ET-1 mRNA expression (Hernandez-Perera et al., 1998,
2000; Mueck et al., 1999; Ozaki et al., 2001; Ohkita et al., 2006) in ECs.
Statins also suppress basic ﬁbroblast growth factor-induced up-
regulation of ETA and ETB receptors (Xu et al., 2002). Of importance,
statins normalize abnormal ET-1 signaling in diabetes. Lee et al.
(2003) found that chronic treatment with atorvastatin prevents coro-
nary atheroma and the enhanced myoplasmic Ca2+ level and tyrosine
phosphorylation responses to ET-1, but does not decrease plasma
cholesterol in diabetic dyslipidemia. Nakamura et al. (2001) reported
that treatment of patients with T2DM exhibiting microalbuminuria
and dyslipidemia with cerivastatin lowers urinary albumin excretion
and circulating ET-1 levels. We found that enhanced ET-1-induced
vascular contraction in OLETF rat is caused by an increase in kinase
suppressor of Ras 1 (KSR1)/ERK complexes after protein phosphatase
2A (PP2A) activation (Nemoto et al., 2012b) and that treatment of
OLETF rats with pravastatin improves ET-1-induced contractions and
suppresses ET-1-induced ERK phosphorylation, with the associated
phosphorylated KSR1 and phosphorylated PP2A levels being increased
toward normal levels. These data suggest that in T2DM rats, pravastatin
normalizes ET-1-induced contraction via a suppression of PP2A/KSR1/
ERK activities (Nemoto et al., 2012b).
Calciumdobesilate,which is considered anangioprotective drug, has
been used in the treatment of diabetic retinopathy and chronic venous
insufﬁciency in various countries during the last few decades (Berthet
et al., 1999; Allain et al., 2004). Although its efﬁcacy and detailedmolec-
ular mechanisms in the treatment of diabetic retinopathy are still
unclear, there are several reports suggesting that this compound has
beneﬁcial effects on retinal ECs (Leal et al., 2010). Javadzadeh et al.
(2013) found that the administration of this compound in patients
with diabetic retinopathy reduces circulating levels of ET-1 and C-
reactive protein (CRP), a marker of systemic inﬂammation. Althoughfuture investigations on themolecularmechanisms of calcium dobesilate
are required, these results indicate that beneﬁcial effects of calcium
dobesilate on diabetic retinopathy may be through a reduction of ET-1.
A number of epidemiologic studies have demonstrated that the
consumption of functional foods containing bioactive polyphenols is
associated with normalization of metabolic and/or vascular dysfunction
(Munir et al., 2013; van Dam et al., 2013). There is a growing body of
evidence suggesting that green tea polyphenols, especially the most
abundant green tea catechin, epigallocatechin gallate (EGCG), have ben-
eﬁcial effects on cardiovascular and metabolic health (Babu and Liu,
2008). For example, EGCG has anti-inﬂammatory, anti-angiogenic, and
anti-proliferative effects on both ECs and VSMCs (C.J. Wang et al.,
2010; Yang et al., 2013). Considering possible effects of EGCG on the
ET-1 system, Reiter et al. (2010) observed that EGCG decreases the ex-
pression and secretion of ET-1 in ECs partly via Akt- and AMPK-
stimulated forkhead box protein O1 (FOXO1) regulation of the ET-1
promoter. C.J. Wang et al. (2010) found that EGCG inhibits ET-1-
induced CRP expression by suppressing reactive oxygen species (ROS).
Moreover, we recently found that long-term treatment of OLETF rats
at the chronic stage of T2DM with EGCG suppresses ET-1-induced con-
traction in large arteries and normalizes endothelial function
(Matsumoto et al., 2013). Resveratrol, a plant-derived stilbene polyphe-
nol found in red wine, has various vasculoprotective effects, such as in-
creased transcription and action of NO synthase (Wallerath et al., 2002),
anti-inﬂammatory effects (Jimenez-Gomez et al., 2013), and induction
of potent endothelium-independent relaxation (Novakovic et al.,
2006). Resveratrol reduces ET-1 production as well as ET-1 effects
(El-Mowafy et al., 2009; Liu et al., 2003; Lopez-Sepulveda et al.,
2011; Nicholson et al., 2010). Resveratrol activates SIRT1 [sirtuin
(silent mating type information regulation 2 homolog) 1], which is a
key regulator of metabolic pathways and stress resistance and has
anti-inﬂammatory, anti-apoptotic, and anti-senescent effects in ECs
(Schmitt et al., 2010). Yang et al. (2010) found that resveratrol increases
SIRT1 expression and NO production stimulated with insulin in HUVEC
under high glucose conditions. Resveratrol also counteracts up-
regulation of ET-1 mRNA and E-selectin induced by high glucose via
SIRT1-independent and -dependentmechanisms, respectively. Themo-
lecular mechanisms by which resveratrol modulates vascular ET-1 ex-
pression remain unclear, and further research is required. These
results suggest that consumption of functional food such as polyphenols
may play an important role to suppress the ET-1 system in diabetic
states. It is important to mention that despite the strong evidence on
the vasculoprotective effects of polyphenols, no studies to date have
conﬁrmed the beneﬁts of polyphenols in diabetic patients. Additional
research, focusing on diabetic patients and using a range of doses, is
needed to advance the ﬁeld.
Oxidative stress plays an important role in diabetes-associated
vascular complications (Hink et al., 2001). ROS generation induces ET-1
synthesis via transforming growth factor-β (TGF-β) (Kahler et al., 2000;
Sugo et al., 2001) and ET-1 enhances ROS generation via NAD(P)H
oxidase in ECs (Dong et al., 2005). Apocynin, an inhibitor of NAD(P)H
oxidase, abrogates hypoxia-induced increased ET-1mRNA levels in carot-
id arteries frommale SD rats (Liu et al., 2013) and abolishes ET-1-induced
activation of the MAPK in aortic VSMC under high glucose conditions
(Banes-Berceli et al., 2005). Bardoxolone, an oral antioxidant and
inﬂammation-modulator, increases renal function in patients with
chronic kidney diseases associated with T2DM (Pergola et al., 2011a,
2011b). Considering that a decrease in ROS generation abrogates
diabetes-induced vascular damage, the use of antioxidants that modu-
late ET-1 signaling may be clinically important in the treatment of this
disease.
Effects of ET-1 receptor blockade on diabetic vasculopathy
Diabetes, obesity, and insulin resistance are associated with in-
creased ET-1 expression and activity, and ET-1 is an important
133T. Matsumoto et al. / Life Sciences 118 (2014) 129–135contributor to the abnormalities in vascular tone, including impaired
endothelium-dependent relaxation and insulin resistance in these
conditions (Matsumoto et al., 2008; Ergul, 2011; Shemyakin et al.,
2011; Pernow et al., 2012; Mather, 2013). Moreover, blockade of ET-
1 signaling improves vasodilation in diabetes and obesity, and antag-
onism of ET-1 actions in the vasculature improves insulin resistance
(Kanie and Kamata, 2002; Shemyakin et al., 2006; Ahlborg et al.,
2007; Lteif et al., 2007; Ergul, 2011; Pernow et al., 2012; Rafnsson
et al., 2012; Mather, 2013). For example, ETA antagonists have beneﬁ-
cial effects on diabetic vascular dysfunction, including increased
blood ﬂow in the retina (Z. Wang et al., 2010), skin microcirculation
(Settergren et al., 2008), and increased forearm blood ﬂow (Cardillo
et al., 2002), and attenuated diabetes-associated aortic atherosclerosis
(Watson et al., 2010). ETA receptor antagonists as well as combined
ETA/ETB antagonists in rats with STZ-induced diabetes decreased pro-
teinuria and normalized the renal matrix protein (Hocher et al., 2001)
and improved endothelium-dependent relaxation in the aorta (Kanie
and Kamata, 2002). On the other hand, ETB antagonism might produce
undesirable effects since, in some cases, ETB blockade exacerbates ET-1
contraction and decreases vascular relaxation, which might be due to
the suppression of EDRFs signaling (Ergul, 2011). Since the activation
of ETB receptor can lead not only to vasorelaxation, but also to vasocon-
striction, a detailed understanding of the role of ETB receptors and the
balance between ETA and ETB receptors in the systemic vasculature
(or in speciﬁc vascular beds) is required when ET antagonists are con-
sidered in the treatment of diabetic vasculopathy. At present, selective
ETA antagonists have been approved only for restricted clinical uses, in-
cluding prostate cancer metastasis prevention (atrasentan) and prima-
ry pulmonary hypertension (bosentan) due to toxicity concerns. Very
recently,macitentan, a newdual ET receptor antagonist that signiﬁcant-
ly reduces morbidity and mortality in patients with pulmonary arterial
hypertension (Pulido et al., 2013), has been approved for the treatment
of pulmonary hypertension. A large phase 3 trial (ASCEND— a random-
ized, double blind, placebo controlled, parallel group study to assess the
effect of the endothelin receptor antagonist avosentan on time to dou-
bling of serum creatinine, end stage renal disease or death in patients
with type 2 diabetes mellitus and diabetic nephropathy) examined
the effects of avosentan, a potent, and non-peptidergic selective ETA re-
ceptor antagonist, on renal disease progression in diabetic nephropathy
(Mann et al., 2010; Benz and Amann, 2011; Kohan and Pollock, 2013).
Treatment with avosentan decreased proteinuria after 3–6 months
treatment (Mann et al., 2010). However, the study was terminated
due to increased morbidity and mortality associated with avosentan-
induced ﬂuid retention. Phase 2 trials with lower doses of avosentan
(than in the ASCEND), atrasentan, and sitaxsentan (the latter two
being highly ETA-selective antagonists) showed reductions in protein-
uria on top of the RAAS blockade (Kohan et al., 2011a; Kohan and
Pollock, 2013). Infrequent and clinically insigniﬁcant ﬂuid retention
was observed at themost effective doses. Additional trials using ETA an-
tagonists are being performed and planned in patients with diabetic ne-
phropathy (Kohan and Pollock, 2013). Moving forward, such studies
must be performed with careful selection of patients and attention to
dosing in order to minimize adverse side effects.
Conclusions
Although the mechanisms involved in the development and pro-
gression of diabetic vasculopathy are still unknown (partially due the
number of factors related to these processes), ET-1 undoubtedly plays
a key role in the pathogenesis and progression of diabetic vasculopathy.
This brief review summarizes the relationship between the ET-1 system
and the current therapeutic strategies for diabetes. Several drugs for
diabetes directly and/or indirectly affect the vascular ET-1 system.
Moreover, a number of experimental studies demonstrate that the
blockade of ET-1 signaling has beneﬁcial effects on diabetic vascular
dysfunctions. Although it is currently unclear whether the associationof ET-1 antagonists and other therapeutic drugs will be beneﬁcial,
experimental and clinical evidence indicate that ET-1 blockade is impor-
tant against diabetic vasculopathy.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.lfs.2013.12.216.
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